Plain-English translation of NCT04812366 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether using genetic information about your prostate cancer can help doctors choose the best combination of medications for you. Researchers will analyze your cancer's DNA to understand which genes are changed, then assign you to receive a personalized combination of medications—which may include apalutamide, abiraterone acetate, , niraparib, or —followed by surgery to remove your prostate.
Standard prostate cancer treatments work well for some men but not others. This study aims to find out whether matching medications specifically to your tumor's genetic profile could make treatment more effective and improve your chances of a good outcome.
You likely qualify if…
You likely don't qualify if…
You will start by receiving hormone therapy plus apalutamide for at least 8 weeks while your cancer tissue is sent to a laboratory for genetic testing. A pathologist will analyze your tumor's DNA to identify specific genetic changes. Based on those results, you will be assigned to one of four personalized treatment arms and receive your assigned medication combination for 16 weeks. At the end of treatment, you will undergo surgery to remove your prostate. Throughout the study, you will have regular clinic visits for blood tests, imaging, and check-ups to monitor your health and treatment response.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States